ImpactRx Brings in Greg Ellis as New CEO
In the US, pharma market research firm ImpactRx has appointed industry veteran Gregory Ellis as President and Chief Executive Officer, replacing Richard Altus who is leaving the firm just months after it was acquired by the parent of retail intelligence giant SymphonyIRI.
Ellis, who previously worked for IRI, has also held senior roles at Nielsen and Opinion Research Corporation. Most recently, he served as a Senior Partner at digital marketing agency Rosetta, where he led the firm’s patient and physician segmentation efforts.
Symphony Technology Group (STG) acquired a majority interest in ImpactRx back in April. The firm uses proprietary panels, custom research and analytics to measure the impact of pharma promotion on physicians’ prescribing behaviour.
ImpactRX Board Member J.T. Treadwell comments: ‘We are very excited to bring Greg on as CEO to lead ImpactRx through its next phase of growth. He brings a terrific background in uniting market research, analytics and consulting to drive innovation and create value for clients.’
Treadwell thanked Altus for his ‘significant contributions’ to the company. It is not yet known what Altus’ next career move will be.
Web site: www.impactrx.com .